In July 2016 Boehringer Ingelheim Pharmaceuticals, Inc. received a Supplemental Approval letter from the FDA concerning a label change about fatal cases of ketoacidosis which have been reported concerning Jardiance, Synjardy, and Glyxambi. These relatively new diabetes medicines are part of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors … [Read more...]
Surgery Improves Quality of Life for Patients With Malignant Pleural Mesothelioma
Undergoing pleurectomy and decortication (PD) for malignant pleural mesothelioma (MPM) generally leads to improved quality of life after the surgery. These findings were presented at the 2016 American Society of Clinical Oncology Annual Meeting. Many patients with malignant pleural mesothelioma avoid the operation because they fear it will … [Read more...]
All SGLT2 Inhibitors Now Investigated for Increased Risk of Amputation
As discussed in my post, Are Invokana & Invokamet Linked to Increased Risk of Toe Amputations?, the European Medicines Agency (EMA) warned in April of 2016 that the popular diabetes drugs, Invokana and Invokamet (canagliflozin), were linked to an increased risk of amputations, especially of the toes. These drugs belong to the sodium glucose … [Read more...]
Viagra / Cialis / Levitra – Melanoma: July 2016 Medical / Legal Update
The FDA is going to study a potential link between melanoma skin cancer and erectile dysfunction (ED) drugs such as Viagra, Cialis, and Levitra, according to information set forth in this document “January – March 2016: Potential Signals of Serious Risks/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS)”. In … [Read more...]
Teacher Developed Cancer From Asbestos
The case of a former Queensland science teacher who was diagnosed with cancer after working with equipment made from asbestos is not isolated, his lawyers say. The 69-year-old, who has requested not to be named, taught in a Toowoomba school for over a decade in the 1970s and 80s. A former science teacher has been diagnosed with … [Read more...]
Doctors Are Concerned About Lack Of Savaysa Antidote To Stop Bleeding
I think it is interesting how this recent Healio – HemOnc Today news reports, “Edoxaban safe, effective for extended prevention of recurrent VTE”, ends by focusing on the continuing lack of any FDA-approve antidote for Savaysa, as well as Eliquis and Xarelto. The growing availability of agents for the reversal of bleeding caused by direct oral … [Read more...]
- « Previous Page
- 1
- …
- 64
- 65
- 66